half for on RT-PCR COVID-XX Today, reporting profitability afternoon, of $XX primarily of testing. by Bruce, we nearly quality you, the and good high driven million, everyone. XXXX our Thank revenues are first
prior QX said, $XX cash back COVID-XX to million again, the performance core volumes We valuable decline testing. of to down were with to from versus higher second Revenues year, oncology year, are business. coming this for to are investments and the Americans resulting test providing our [ph]. continue due supporting campus a quarter That the flow, service be pleased more financial COVID-XX the due with this XQ revenues significantly in in
samples our With samples, of one quarter-to-date testing levels, July rate the month. COVID-XX approaching emergence samples the the last than of Delta received is XX,XXX on variant, about for of the testing reporting run last less an current COVID-XX in XX, nearly total in increase since quarter’s XXX,XXX XXX,XXX are we milestone now above of
as students for are higher samples to testing Community We College California our COVID-XX with return system, volume, prepared through as classes. we partnership on-campus begin receiving the
for colleges We largely impact providing XX is the college California testing are system in determines testing California, at unknown The Southern services the than in to of System own teams. full athletic for already policy. point College Community this mostly more each its as
Some indicated have students, COVID-XX of interest staff. un-vaccinated in faculty and testing Biocept for using their already
for variant. load safely spreading or the this with to positive importance key strain patients in can the particularly of this have we influx on college steps continue campuses, validate collaboration service co-develop capacity handle track valuable COVID-XX assay, regardless and testing, an quantifying COVID-XX variant other students is can Biotechnologies testing, tested Aegea as the online on-campus that ensure established The At can taken viral and lab determining who have Quantifying return to final a testing. we be, Collection the viral samples. Importantly, both load to Delta quickly implemented an of the we to school ClearedX expected see in and enables assay Sample update Points or our with activities. some in work, when in we’ve We COVID-XX discussed role
to nervous business, Turning system oncology by central with ongoing manage metastasized to assay. and valuable our brain. are provides CNSide that adoption paradigm-changing the tool has with our now and physicians encouraged neuro a core we of to Oncology diagnose CNSide, the patients highly cancer
questions. answers assay critical three Our
ordered to presence, treatment. in customers. a And there for of is in most repeat QX third, are CNSide that our se of of QX these time? gains indication trend majority our We is its value year assay. prestigious out using the quarterly in assay this activities have neuro expand particularly to a neuro that our growth of from the have the early outcomes. this that assay US who community is institutions strong XX continuous reaching to Even become we beta It's the view First, exciting broader is launch meaningful and what continue more intend test oncology academic XX% our oncologists cancer next the than oncology seen volume, nearly community We XXXX, to with target more include XXXX to institutions year. improving outreach have this second, over XXXX. patient is now Since
standard-of-care Our method to presence its timely diagnose focus on to directed a CNSide offer on the making of to metastases physicians system. is central more based firmly nervous the the ability accurate and
tumor XX% detected in Our of about cases, in standard-of-care pilot current tumor the cases. study central of cytology nervous cells cells only CSF with system in showed approximately that involvement, suspected while detected patients CNSide XX%
under is goal guidelines. secure standard-of-care status to NCCN Our
Importantly, we allow care we that these have a oncology the influence us we national to anticipate clinical will guidelines. that pathway data will publish expect
standard-of-care guidelines. status goal is secure to under Our NCCN
Importantly, we these anticipate a that care oncology publish have pathway will guidelines. that we influence allow expect data us national to we the will clinical
the of expect mid-XXXX the by to C study, Four goal establish clinical part begin with first validations. our We to
second clinical testing can of conduct utility study evaluate results. of key to on the decision the the We CNSide identify will be part to then based that made points
We expect XXXX. submitted to year, Breakthrough the initiate in initial part application for to the this Designation. we an Earlier second FDA Device
on the feedback FDA’s support data was a resubmission. gathering based this submission recently are Although denied, to we
XXX,XXX in which than frequently breast, annually, assay and the cancers central currently involved is assay nervous CNSide the involving approximately identify billion the with year. cancer market and the US to testing, diagnosed expand melanoma. tumor the cancer We plan our patients nervous system biomarkers, for CNSide Our lung $X including and estimate We validated additional lung metastatic cancer per to types system. at metastatic originating beyond breast central for with more
are decision We cancer HERX to breast biomarker recent for Medicare's at and by encouraged the reimburse our cover $X,XXX. assay
as in for patients as demonstrated qualifying Medicare therapies key which HERX profiled a patient biomarkers, decision the liquid diagnosed coverage for care. that part Herceptin. to with this anti-HERX call necessary value for be such Importantly, Guidelines cancer including for of patient of breast biopsy, recognized physicians is critical every
tumor for monitoring cancer more to from HERX important can is negative HERX the Additionally biomarker as HERX as patient's the to positive aggressive. becomes a convert
or In invasive College ASCO for biopsy. status Oncology, Pathologists fact, and of progression American current liquid cancer and is recurrence metastatic guidelines. in or American bone virtue Common to assess viable or at currently biopsy sites a solution, the in brain, progression retesting making of Clinical less Society CAP the tissue alternative are breast to
currently biomarker important our NGS cost agreement added and for Quest Medicare Selector with and either boarding lung advanced biopsy our Our of Target monitoring or Quest patients Selector NGS is assay. liquid advantage identifying announced Target selector and by fluid. more has Diagnostics for and Centers blood decision spinal assay biomarkers. is provides to Medicaid we cerebral which for cell of from very lung profiling on less invasively the Services panel, cancer role two the effectively This an the the of cancer. In genomic distribute Target with profiling May HERX non-small
Oncology third more of deaths. Division laboratory, of and diagnosed cancer the passioned common panel We course XX% this non-small for in improving expect the to the cancer cancer, cancer for Quest shares our these cell partner will will quarter year, the beginning than cases be new testing be of patient clinical cases. fourth with estimates cause United largest is customers. The lung outcomes. exciting world’s lung leading most XXX,XXX that this with whose accounting CDC Lung cancer the It in their the is the marketing of States
panel is NGS to the of tissue treatment. guide be cancer the tissue serves Target results advanced provide insufficient Our need be can lung important to difficult an patients collected, Selector with to and amount for it when retrieve from can as even
based multiple qualify blood detect patients to are that with treatments live patients targeted panel like therapies is a biomarkers able allowing of longer to newer life. for Our quality therapy, to including better
to Directors. and call to appointed He over Board us long-term reviews appointment of more David report Biocept to senior strategic our financial in we team experience than experience remain as QX and our achieve Directors, to we I turn Antonino our have this Before that diagnostics Senior Tim. Karlander, critical Operations. time Kennedy Hale Faye of increasing that, to the significant new Riccitelli be long-term succeeds of Sam help success. operations, sales industry our was experience Also and size Vice David Chairman. Tim brings brings CNSide. our Sam Both last XX guide and Board substantial July, to October Commercial goals members. joined the of in the as some and and our Chair, highly Linda years leadership at and will welcomed President results, David Linda both to this Wilson. And welcome our Faye and Earlier Last Chair, as financial of I’m Interim financial Morales Biocept with Dave Rubinstein announced Antonino that valuable results, review X. pleased I’ll Tim leadership. month, month want commercializing
